Huberman Lab: Peptides, GLP-1s & Safety Risks Explained with Dr. Abud Bakri

Peptides represent a complex language of cell-to-cell communication, yet a sharp divide exists between clinically validated drugs like GLP-1 agonists and experimental compounds like BPC-157. While BPC-157 shows promise for tissue repair in animal models, the absence of human safety data and LD50 metrics creates significant systemic risk, especially as its effects may be localized to the gut rather than systemic. The normalization of self-injection through weight-loss drugs has fueled the popularity of a "Trinity Stack"—combining GLP-1s, growth hormones, and androgens—often sourced from unregulated gray markets with inconsistent quality control. Emerging research into the thymus and Russian bioregulators like epitalon suggests potential for immune rejuvenation and DNA modulation, though these findings lack rigorous human trials. Effective use requires strict physician oversight and biomarker monitoring, such as tracking IGF-1 levels, to navigate the blurred line between medical innovation and unregulated experimentation.